Hipertermia maligna no Brasil: análise da atividade do hotline em 2009
Malignant hyperthermia in Brazil: analysis of hotline activity in 2009
Helga Cristina Almeida da Silva; Clea dos Santos Almeida; Julio Cézar Mendes Brandão; Cleyton Amaral Nogueira e Silva; Mariana Elisa Pinto de Lorenzo; Carolina Baeta Neves Duarte Ferreira; André Hosoi Resende; Sara Rocha Barreira; Priscilla Antunes de Almeida; Leonardo Henrique Cunha Ferraro; Alexandre Takeda; Kátia Ferreira de Oliveira; Talitha Gonçalez Lelis; Alexandre Hortense; Marcelo Vaz Perez; Beny Schmidt; Acary Souza Bulle Oliveira; José Luiz Gomes do Amaral
Resumo
Palavras-chave
Abstract
Keywords
References
Silva HCA, Tsanaclis AMC, Amaral JLG. Hipertermia maligna. 2008.
Rosemberg H, Sambuughin N, Dirksen R. Malignant hyperthermia susceptibility. 2010:1-30.
Muniz VP, Silva HC, Tsanaclis AM. Screening for mutations in the RYR1 gene in families with malignant hyperthermia. J Mol Neurosci. 2003;21(1):35-42.
Vainzof M, Muniz VP, Tsanaclis AM. Does the A3333G mutation in the CACNL1A3 gene, detected in malignant hyperthermia, also occur in central core disease?. Genet Test. 2000;4(4):383-6.
Pereira JB, Castro DL, Lucchesi NO. Hipertermia maligna durante cirurgia de estapedectomia. Rev Bras Anestesiol. 1975;25:3-12.
Sistema de Informações Hospitalares do SUS (SIH/SUS). .
Amaral JLG, Silva HCA. Anais do V Simpósio Brasileiro de Hipertermia Maligna. Rev Neurociênc. 2005;13(3^sSuplemento):1-94.
Larach MG, Localio AR, Allen GC. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology. 1994;80:771-779.
Dubowitz V. Muscle biopsy: a pratical approach. 1985:3-220.
Ellis FR, Halsall PJ, Ording H. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth. 1984;56:1267-1269.
Lei nº 10.781, de 9 de março de 2001. Diário Oficial. 7/9/;111(170).
Decreto 46.601, de 12 de março de 2002. Diário Oficial. 13/3;112(47).
Resolução SS-23, de 27 de fevereiro de 2004: Aprova Norma Técnica relativa às diretrizes para diagnóstico, tratamento, prevenção, notificação e investigação epidemiológica dos casos de hipertermia maligna. Diário Oficial, Poder Executivo. 28/2;114(39):17-19.
Teixeira P. Hipertermia maligna, legislação no Estado de São Paulo. Revista Neurociências. 2005;13(3^ssupl):21-25.
Parris WCV, Kambam J, Adkins B. Typical and atypical presentation of malignant hyperpyrexa in nonwhite patients. Anesth Prog. 1988;35:208-211.
Wang YL, Luo AL, Tan G. Clinical features and diagnosis for Chinese cases with malignant hyperthermia: a case cluster from 2005 to 2007. Chin Med J. 2010;123(10):1241-1245.
Stamm DS, Aylsworth AS, Stajich JM. Native American myopathy: congenital myopathy with cleft palate, skeletal anomalies, and susceptibility to malignant hyperthermia. Am J Med Gen. 2008;146A:1832-1841.
Kossugue PM, Paim JF, Navarro MM. Central core disease due to recessive mutations in RYR1 gene: is it more common than described?. Muscle Nerve. 2007;35(5):670-674.
Monnier N, Krivosic-Horber R, Payen JF. Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. Anesthesiology. 2002;97(5):1067-1074.
Barbier M, Lafaye AL, Guerin R. A case of malignant hyperthermia arising five hours after the beginning of anaesthesia with sevoflurane and after five uneventful surgical procedures. Ann Fr Anesth Reanim. 2009;28:983-987.
Denis A, Mergaert L, Fostier C. Issues surrounding orphan disease and orphan drug policies in Europe. Appl Health Econ Health Policy. 2010;8(5):343-350.
Resolução CFM Nº 1.802/2006: Dispõe sobre a prática do ato anestésico. 1 de.
Kugler Y, Russell WJ. Speeding dantrolene preparation for treating malignant hyperthermia. Anaesth Intensive Care. 2011;39(1):84-8.
Larach MG, Gronert GA, Allen GC. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg. 2010;110:498-507.
Halsall PJ, Ellis FR. Does postoperative pyrexia indicate malignant hyperthermia susceptibility?. Br J Anaesth. 1992;68(2):209-210.
Roy S, Fortier LP. Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine. Can J Anesth. 2003;50(1):32-35.
Glahn KP, Ellis FR, Halsall PJ. Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group. Br J Anaesth. 2010;105(4):417-420.
Rosero EB, Adesanya AO, Timaran CH. Trends and outcomes of malignant hyperthermia in the United States, 2000 to 2005. Anesthesiology. 2009;110(1):89-94.
Brady JE, Sun LS, Rosenberg H. Prevalence of malignant hyperthermia due to anesthesia in New York State, 2001-2005. Anesth Analg. 2009;109:1162-1166.
Larach MG, Brandom BW, Allen GC. Cardiac arrests and deaths associated with malignant hyperthermia in North America from 1987 to 2006: a report from the North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States. Anesthesiology. 2008;108:603-611.